DeepMind Spinout Isomorphic Labs Raises $2.1 Billion to Design Drugs With AI

Isomorphic Labs raised $2.1 billion in its second round of outside capital, with new backing from sovereign wealth funds, underscoring strong investor demand for AI-designed drug development. The financing supports the company’s effort to turn artificial intelligence-designed drugs into reality. The news is positive for Alphabet’s innovation pipeline, though the direct near-term market impact is likely limited.

Analysis

Isomorphic Labs raised $2.1 billion in its second round of outside capital, with new backing from sovereign wealth funds, underscoring strong investor demand for AI-designed drug development. The financing supports the company’s effort to turn artificial intelligence-designed drugs into reality. The news is positive for Alphabet’s innovation pipeline, though the direct near-term market impact is likely limited.